Navigation
banner
Together we Drive the Future

Genomics & Big Data Summit

2017-08-192017-08-262017-07-26
EARLY BIRD DISCOUNT! Register by Aug 26, 2017 to receive 10% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


PLENARY KEYNOTE SPEAKERS
Kay Eron

Kay Eron
General Manager, Health & Life Sciences Data Center Group
Intel Corporation
Kay Eron
General Manager, Health & Life Sciences Data Center Group
Intel Corporation
 
About Speaker:

Kay Eron is GM of the Health & Life Sciences in Intel’s Datacenter Solutions Group. She leads a worldwide team building analytics solutions in genomics and medical imaging.

Kay came to Intel from GE Healthcare, where for over 10 years she managed a P&L of R&D, product management, sales, and marketing teams to develop innovative health IT solutions and connected devices that enhance the quality of care.

Kay is an inclusive, collaborative, high-performing leader with a track record of building solid partnerships with external companies, including leading providers, electronic medical record (EMR) companies, medical device manufacturers, key industry groups, research institutes, and multiple software application vendors supporting the health IT marketplace.  

Kay also has worked for McKinsey & Company, as well as GE Ventures, where she led industry analysis, developed strategies and roadmaps for key growth technologies.

Iain Fraser

Iain Fraser
Chief, Signaling Systems Unit
NIH
Iain Fraser
Chief, Signaling Systems Unit
NIH
 
About Speaker:
Jeffery Schloss

Jeffery Schloss
Former Director of the Division of Genome Sciences
Independent Scientist, Formerly with NIH
Jeffery Schloss
Former Director of the Division of Genome Sciences
Independent Scientist, Formerly with NIH
 
About Speaker:

Jeffery A. Schloss, Ph.D., is experienced in running programs to develop and implement genomic technologies.  He was most recently Director, Division of Genome Sciences, Extramural Research Program, National Human Genome Research Institute (NHGRI), U.S. National Institutes of Health, where he supervised the scientists who were responsible for well-known, productive programs such as NHGRI’s Genome Sequencing Program, ENCODE, 1000 Genomes, $1,000 Genome Technology program, and much of NHGRI’s informatics program, and NIH Common Fund programs including KOMP, LINCS, H3Africa, Protein Capture, and the Human Microbiome Program.  Earlier, as Program Director at NHGRI, Schloss developed and implemented the program to develop technologies to sequence human genomes at a cost of $1,000, and the Centers of Excellence in Genomic Science; in the early days of the Human Genome Project he managed grants to centers that were building human and model organism physical and genetic maps, and helped initiate the scale-up to HGP sequencing.  Schloss served on numerous trans-NIH and trans-federal-agency programs including the NIH Bioengineering Consortium and the National Nanotechnology Initiative. He was on the biology faculty at the University of Kentucky after a postdoc in the biology department at Yale University and earning the PhD degree in cell biology at Carnegie Mellon University.

PLENARY SPEAKERS
Leah Lowthorp

Leah Lowthorp
Program Manager
Center for Genetics and Society
Leah Lowthorp
Program Manager
Center for Genetics and Society
 
About Speaker:

Leah Lowthorp, Ph.D., is Program Manager and ACLS Public Fellow at the Center for Genetics and Society (CGS), a leading public interest organization that works to encourage responsible uses and effective societal governance of human genetic and assisted reproductive technologies. She brings expertise in the ethics and policy implications of emerging human biotechnologies, with a focus on human gene editing and 3-person in-vitro fertilization techniques. Prior to joining CGS, Leah taught at Harvard University and the University of Pennsylvania.

Metabolomics - Advances & Applications in Human Disease
DISTINGUISHED SPEAKERS
Abhishek Jha

Abhishek Jha
Co-founder
Elucidata
Abhishek Jha
Co-founder
Elucidata
 
About Speaker:
Mike Milburn

Mike Milburn
Chief Scientific Officer
Metabolon, Inc.
Mike Milburn
Chief Scientific Officer
Metabolon, Inc.
 
About Speaker:

Dr. Milburn has served as Chief Scientific Officer since 2005 and is responsible for global metabolomics technology development, laboratory operations, informatics, and data science. Before joining Metabolon, he was Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals, where he led the preclinical/clinical development of drugs in metabolic disease and neurodegeneration. Prior to Sirtris, Dr. Milburn was Senior Vice President of Research at Plexxikon and was responsible for the development of its proprietary high-throughput, scaffold-based chemical technology platform. He also held various research positions at Glaxo and GlaxoWellcome from 1991 to 2001. Dr. Milburn received his PhD in biophysical chemistry from the University of California, Berkeley and was a post-doctoral research fellow at Harvard Medical School.

Wimal Pathmasiri

Wimal Pathmasiri
Research Assistant Professor, Department of Nutrition
Nutrition Research Institute, University of North Carolina at Chapel Hill
Wimal Pathmasiri
Research Assistant Professor, Department of Nutrition
Nutrition Research Institute, University of North Carolina at Chapel Hill
 
About Speaker:

Wimal Pathmasiri, Ph.D. joined the UNC Nutrition Research Institute in March 2017 as a Research Assistant Professor in the Department of Nutrition, UNC-Chapel Hill. Dr. Pathmasiri is interested in identifying signature metabolite profiles related to disease state and the outcome of nutritional intervention to disease. He will focus on effect of diet and naturally occurring molecules in diet on gut microbiome related metabolism.

Dr. Pathmasiri earned his B.Sc. and M.Phil. from the University of Colombo, Sri Lanka, and a Licentiate of Philosophy from the Uppsala University, Sweden. He received his Ph.D. in Chemistry from Uppsala University and did postdoctoral work at the UNC Chapel and RTI International. He has been working as a Research Biochemist before joining the UNC NRI.

He is an active member of the NIH Common Fund Eastern Regional Comprehensive Metabolomics Resource Core (ERCMRC). As a metabolomics scientist, he has contributed to collaborative metabolomics research on a number of research areas: cancer, childhood obesity, early life exposure to antibiotics, environmental exposure, kidney disease, osteoarthritis, rare diseases, and toxicology.

John Ryals

John Ryals
President and CEO
Metabolon, Inc.
John Ryals
President and CEO
Metabolon, Inc.
 
About Speaker:
Natalie Serkova

Natalie Serkova
Professor
University of Colorado Anschutz Medical Campus
Natalie Serkova
Professor
University of Colorado Anschutz Medical Campus
 
About Speaker:

Dr. Natalie J. Serkova is Director of the University of Colorado Cancer Center/ CTSA Imaging and Metabolomics Core. She received her BS in Physics at the Fourier Institute in Grenoble (France), MS in Biophysics at the University of Kiev (Ukraine) and her MD/ PhD was in Medical Physics/ Biochemistry at the Medical School of Hannover and the University of Bremen (Germany). She continued with her postdoctoral training in the area of translational pharmacokinetics/ pharmacodynamics (PK/PD) using LC-MS, NMR spectroscopy, MRI and PET based end-points at the University of California San Francisco and Stanford. Presently, Dr. Serkova is Professor of Anesthesiology, with secondary appointments in Radiology, Radiation Oncology and Pharmacology. Dr. Natalie Serkova and her team evaluate changes in cancer biochemistry and microenvironment by applying translational metabolomics and imaging approaches for animal studies and human trials with novel anti-cancer drugs and radiation-induced inflammation. The technological platforms for her research include NMR-based quantitative metabolomics for biomarker elucidation ex vivo and their translation into non-invasive MRI and PET based metabolic imaging protocols.

Next Generation Sequencing
DISTINGUISHED SPEAKERS
Tyson Clark

Tyson Clark
Director, Applications Development
Pacific Biosciences
Tyson Clark
Director, Applications Development
Pacific Biosciences
 
About Speaker:

Tyson A. Clark, Ph.D. is a Director in the R&D group at Pacific Biosciences who focuses on development of new applications that utilize PacBio’s long read sequencing technologies. Dr. Clark received his doctorate degree in Molecular Biology from the University of California, Santa Cruz in 2002. He was a pioneer in the use of microarrays to study alternative splicing at a genome-wide scale. After working in the gene expression space at Affymetrix, Dr. Clark joined Pacific Biosciences in 2009. He has worked on a broad range of applications of SMRT® Sequencing, including direct detection of modified DNA bases, but his current focus is on the use of long reads for targeted sequencing and to sequence full-length cDNA transcripts.

Joshua Edel

Joshua Edel
Professor of Biosensing & Analytical Sciences
Imperial College London
Joshua Edel
Professor of Biosensing & Analytical Sciences
Imperial College London
 
About Speaker:

Prof. Joshua Edel received his PhD on the development of single molecule detection within microfluidic systems at Imperial College London in 2003. He then performed postdoctoral research in nanobiotechnology at Cornell University within the School of Applied and Engineering Physics. In 2005 he was awarded a research fellowship in single molecule biophysics at the Rowland Institute at Harvard University. In July 2006 he joined Imperial College London within the Department of Chemistry and Institute of Biomedical Engineering as a lecturer. Joshua is currently a Professor in the Department of Chemistry and in 2011 he was awarded a prestigious ERC Starting Grant on “Nanoporous Membranes for High Throughput Rare Event Bioanalysis” and in 2016 he was awarded an ERC Consolidator Grant related to the development of selective single molecule biosensors.

Richard McCombie

Richard McCombie
Professor & Director, The Stanley Institute for Cognitive Genomics
Cold Spring Harbor Laboratory
Richard McCombie
Professor & Director, The Stanley Institute for Cognitive Genomics
Cold Spring Harbor Laboratory
 
About Speaker:
John Oliver

John Oliver
Chief Technology Officer
Nabsys 2.0
John Oliver
Chief Technology Officer
Nabsys 2.0
 
About Speaker:

John Oliver, Ph.D. is the Chief Technology Officer at Nabsys 2.0 LLC where he is responsible for overseeing all aspects of the scientific development of the company’s DNA mapping platform. Dr. Oliver brings over 25 years of research expertise to Nabsys. His diverse experience includes synthetic organic chemistry, biochemistry, molecular biology, surface chemistry, and microarray technology. Dr. Oliver previously served as Chief Scientific Officer at GeneSpectrum Inc. an array-based sequencing company that he co-founded in 2000 with colleagues from Brown University. Prior to founding GeneSpectrum, Dr. Oliver was an assistant professor of Chemistry at Brown University. His research group focused on developing methods of performing non-natural amino acid mutagenesis, identifying novel catalysis mechanisms, and investigating biosynthetic pathways for terpene natural products. Dr. Oliver received a MS and a PhD in Chemistry from Northwestern University in Evanston, IL. He is a graduate of Harvey Mudd College where he received a Bachelor of Science in Chemistry.

Michael Phelan

Michael Phelan
Senior Scientist, R&D
Fluidigm Corporation
Michael Phelan
Senior Scientist, R&D
Fluidigm Corporation
 
About Speaker:
Flora Tassone

Flora Tassone
Professor, Biochemistry and Molecular Medicine; M.I.N.D. Institute Investigator
University of California, Davis, School of Medicine
Flora Tassone
Professor, Biochemistry and Molecular Medicine; M.I.N.D. Institute Investigator
University of California, Davis, School of Medicine
 
About Speaker:

She received a PhD from the Catholic University of Rome, Italy, for her studies on Down Syndrome. During the postdoctoral fellowship, first at the Eleanor Roosevelt Institute in Denver, and then at University of Colorado Health Science Center she continued to work on the identification of genes involved in Down Syndrome and started to focus her attention on the molecular basis leading to Fragile X syndrome and autism spectrum disorders.

In 2001 she moved to the University of California, Davis and focused her research on neurodevelopmental disorders including Fragile X syndrome and associated disorders, autism spectrum disorders and 22q deletion syndrome.

Her expertise is in transcriptional and translational regulation of the fragile X (FMR1) gene. Dr. Tassone has carried out a significant work on the molecular characterization of premutation alleles and the association with a number of clinical features observed in carriers. Dr. Tassone has made a number of important observations related to the mechanism of gene expression of the FMR1 gene, especially regarding the effects of premutation alleles in individuals that the scientific community thought to be clinically unaffected. Specifically, she investigated the clinical manifestations, protein and FMR1 mRNA expression in individuals with fragile X syndrome and made the important discovery of gene dysregulation (increased mRNA activity) among premutation carriers. This discovery provided the molecular basis for the forms of clinical involvement among carriers, including fragile X-associated tremor/ataxia syndrome (FXTAS), which was described in 2001 by her team. Since then, she has been investigating the molecular mechanisms involved in the FMR1- associated disorders.

She has conducted a pilot study on Newborn Screening in Fragile X syndrome, funded by NICHD, the first of its kind in United States, which has generated prevalence data on expanded alleles, using a PCR-based methodology that she developed in her Lab.

With the advent of clinical trials she has been involved in the development of molecular biomarkers predictive of drug efficacy and monitoring disease severity.

Her research is also focused on other neurodevelopmental disorders including autism spectrum disorders and 22q deletion syndrome, since a significant number of children with fragile X syndrome and 22q deletion also have autism. Specifically, she is involved in the identification of susceptibility genes that play a role in the pathogenesis of autism.

Dr. Tassone has extensive experience in medical genetics and clinical analysis. She has been granted multiple awards, fellowships and training opportunities, as well as research awards from NIH and several funding agencies.

John Thompson

John Thompson
Chief Technology Officer
Claritas Genomics
John Thompson
Chief Technology Officer
Claritas Genomics
 
About Speaker:

John Thompson’s career has spanned pharmaceutical, next-gen sequencing, and genetic testing industries. As Chief Technology Officer at Claritas Genomics, he is responsible for improving genetic assays for diagnosing pediatric disease and developing the next generation of assays. At Nabsys, he advanced mapping and sequencing of very long DNAs using fully solid-state nanodetectors. Prior to Nabsys, he was Senior Director of Genomic Research at Helicos BioSciences for four years, helping to develop the first commercial single-molecule, next-generation sequencing platform and apply it to a range of DNA and RNA sequencing applications. Before that, his contributions at Pfizer used molecular biology and genetic approaches to identify novel therapeutic targets, to establish the genetic basis of drug response, and to characterize the genetics of drug-induced adverse events.

Meni Wanunu

Meni Wanunu
Professor, Department of Physics
Northeastern University
Meni Wanunu
Professor, Department of Physics
Northeastern University
 
About Speaker:

Professor of biophysics, interest in single-molecule DNA/RNA sequencing, nanopores, optics, waveguides.

Big Data Bioinformatics
DISTINGUISHED SPEAKERS
Alon Arad

Alon Arad
Computer Vision Lead
ReadCoor
Alon Arad
Computer Vision Lead
ReadCoor
 
About Speaker:

Dr Alon Arad is a computer vision lead at readcoor. Previously held a position as a visiting scientists at MIT in the mathematics department and was also a team lead of image processing at Shell Oil.

Hannah Carter

Hannah Carter
Assistant Professor of Medicine, Division of Medical Genetics
University of California, San Diego
Hannah Carter
Assistant Professor of Medicine, Division of Medical Genetics
University of California, San Diego
 
About Speaker:

The Carter Lab uses computation to study the impact of cancer-associated DNA mutations on intracellular biological processes and cellular behaviors. Current projects focus on identifying variation that contributes to cancer predisposition or that can be exploited for cancer therapy. Dr. Carter is a Siebel Scholar and a recipient of a 2013 NIH Director's Early Independence Award.

Dexter Hadley

Dexter Hadley
Assistant Professor of Pediatrics
Institute for Computational Health Sciences, University of California, San Francisco
Dexter Hadley
Assistant Professor of Pediatrics
Institute for Computational Health Sciences, University of California, San Francisco
 
About Speaker:
Brian Laffin

Brian Laffin
Associate Director Translational Diagnostics
Definiens
Brian Laffin
Associate Director Translational Diagnostics
Definiens
 
About Speaker:
Toby Richardson

Toby Richardson
VP, Bioinformatics
Synthetic Genomics
Toby Richardson
VP, Bioinformatics
Synthetic Genomics
 
About Speaker:

Dr Richardson joined SGI in August of 2006 and has served as VP of Informatics since 2008. He was responsible for initially setting up the informatics and software engineering departments and has led the development and implementation of SGIs proprietary genomics software platform Archetype®. Toby is also responsible for ensuring that SGI is on the cutting edge of the latest NGS platforms and computational biology tools and the implementation of these tools across the R&D groups at SGI. Prior to joining SGI, Dr Richardson spent ten years at Diversa Corporation, where he successfully ran and managed both an enzymology and informatics group and his team developed some of the first tools to annotate, store, and mine metagenomic information from environmental samples. Prior to joining the industrial biotechnology sector, Dr Richardson during his Ph.D and postdoctoral research spent 10 years studying cytochrome P450.

Anurag Sethi

Anurag Sethi
Bioinformatics Scientist
Seven Bridges
Anurag Sethi
Bioinformatics Scientist
Seven Bridges
 
About Speaker:
Alex Sherman

Alex Sherman
Director, Strategic Development & Systems Neurological CRI; Principal Associate in Neurology
Massachusetts General Hospital; Harvard Medical School
Alex Sherman
Director, Strategic Development & Systems Neurological CRI; Principal Associate in Neurology
Massachusetts General Hospital; Harvard Medical School
 
About Speaker:

Alex's interests and passion are in developing collaborations in clinical research and building disease-specific research networks and consortia to achieve “Big Data” in rare diseases. Other areas of his research are understanding the benefits of patient-centric research and incentives for research collaborations and data sharing. He is a frequent speaker at academic and industry conferences and has many publications on the topics of collaboration in clinical research, data and biospecimen sharing and technology utilization for these purposes. As the Director of Strategic Development & Systems at the Neurological Clinical Research Institute at Massachusetts General Hospital, Alex is responsible for the successful design, development and deployment of software platforms for numerous clinical trials and biomarker studies in neurological diseases. Alex conceived and was instrumental in design, development and adoption by the international research community of NeuroBANK™ platform, an accelerated clinical research environment, currently utilized by numerous researchers and institutions worldwide. His team was responsible for conception, design and implementation of PRO-ACT - the largest clinical dataset from clinical trials data in ALS and the first such attempt in a rare diseases space. This platform was selected as the Best Practices winner by the Bio-IT World Congress in 2013 and by Clinical Informatics News in 2016. Alex is a Board Member of the ALS Research Group (ALSRG) and a founding Board Member of ALD Connect research consortium. Mr. Sherman holds Masters of Science degree in Nuclear Engineering and graduated from a doctorate program in Nuclear Engineering. He is a Principal Associate in Neurology at Harvard Medical School.

CRISPR & Genome Engineering
DISTINGUISHED SPEAKERS
Daniel Anderson

Daniel Anderson
Assoc. Prof., Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology
Massachusetts Institute of Technology
Daniel Anderson
Assoc. Prof., Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology
Massachusetts Institute of Technology
 
About Speaker:

Professor Daniel G. Anderson is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in Prof. Anderson’s laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances and products in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science. Prof. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. His work has resulted in the publication of over 300 papers, patents and patent applications. These patents were the basis for the foundation of a number of companies in the pharmaceutical, biotechnology, and consumer products space, and have led to a number of products that have been commercialized or are in clinical development.

Joe Bondy-Denomy

Joe Bondy-Denomy
Faculty Fellow, Department of Microbiology & Immunology
UCSF
Joe Bondy-Denomy
Faculty Fellow, Department of Microbiology & Immunology
UCSF
 
About Speaker:

I have been an independent fellow at UCSF for two years, and transitioning into a faculty position at UCSF in November. I have been in the Department of Microbiology & Immunology for both positions. Prior to this I was a graduate student at the University of Toronto in Alan Davidson's lab.

Jonathan Chesnut

Jonathan Chesnut
Sr. Director, Synthetic Biology R&D
Thermo Fisher Scientific
Jonathan Chesnut
Sr. Director, Synthetic Biology R&D
Thermo Fisher Scientific
 
About Speaker:

Jon Chesnut received a PhD in Cell and Molecular Biology from UC Davis (1994), and did postdoctoral studies at the University of Colorado in recombinant antibody technology development (1994-95). Prior to graduate school, he was employed at the Salk Institute (1983-84) and Hybritech Inc. in La Jolla, CA (1984-88). After his post doctoral research at Colorado he joined Invitrogen as a research scientist (1995). Since then he has led the development of various prokaryotic and mammalian cell cloning and expression systems. He has led groups focused on development of TOPO and Gateway cloning as well as the human embryonic cell engineering technologies. He now leads the Synthetic Biology Research and Development Team in the Life Sciences Solutions Group of Thermo Fisher Scientific in Carlsbad, CA. His group is focused on developing tools for the entire Synthetic Biology and Cell Engineering workflow, specifically Bioinformatics, Genome Editing, and Cellular Analytics.

CB Gurumurthy

CB Gurumurthy
Associate Professor, Developmental Neuroscience
University of Nebraska Medical Center
CB Gurumurthy
Associate Professor, Developmental Neuroscience
University of Nebraska Medical Center
 
About Speaker:

CB Gurumurthy is an Associate Professor of Developmental Neuroscience, Munroe Meyer Institute for Genetics and Rehabilitation, and he serves as the Director of UNMC Mouse Genome Engineering Core Facility at the University of Nebraska Medical Center. He received his BVSC (DVM) from Bangalore Veterinary College, India and MVSC & PHD in Veterinary Virology from Indian Veterinary Research Institute with a Gold Medal distinction in MVSC. Prior to his current position, he served as a Molecular Biology Scientist, Drug Discovery Research at Dr. Reddy’s Laboratories, and then he moved to Northwestern University, Chicago for a Post-Doctoral work in Cancer Biology and Mouse Molecular Genetics. He also received his Executive MBA from University of Nebraska at Omaha. His research interests are improving and development of novel genome engineering technologies.

Eric Ostertag

Eric Ostertag
CEO
Poseida Therapeutics
Eric Ostertag
CEO
Poseida Therapeutics
 
About Speaker:
Edward Rebar

Edward Rebar
VP, Technology
Sangamo Therapeutics
Edward Rebar
VP, Technology
Sangamo Therapeutics
 
About Speaker:
Garrett Rettig

Garrett Rettig
Sr. Staff Scientist, Molecular Genetics
Integrated DNA Technologies
Garrett Rettig
Sr. Staff Scientist, Molecular Genetics
Integrated DNA Technologies
 
About Speaker:

Garrett has been at IDT since 2008. During that time, he has been primarily involved in high-throughput in vitro screening of siRNAs, as well as other oligonucleotide-based technologies in cell biology applications. Most recently, he has been focused on developing CRISPR technologies at IDT and applying Next Generation Sequencing strategies to detecting on-target and off-target editing events.

Ron Weiss

Ron Weiss
Professor
MIT
Ron Weiss
Professor
MIT
 
About Speaker: